Nucala gains new indication; FDA implements stricter guidance for COVID-19 vaccine approval; pruritus reported following discontinuation of long-term antihistamines; antibiotic looks promising for ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

Topline results were announced from two phase 3 trials evaluating itepekimab, an anti-interleukin-33 monoclonal antibody, in former smokers with inadequately controlled chronic obstructive pulmonary ...

Statins recommended for persons with HIV with a 10-year ASCVD risk score of 5 percent or higher; favored for those with risk score ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

“Banning NIH-funded researchers from publishing in leading medical journals and requiring them to publish only in journals that carry the RFK Jr. seal of approval would delegitimize taxpayer-funded ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

The Food and Drug Administration (FDA) has approved Khindivi ™ (hydrocortisone) oral solution as a replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency.

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

As of mid-May, this variant has been identified in nearly 11% of sequenced samples reported worldwide. The WHO has designated this variant as a “variant under monitoring,” and currently assesses the ...